Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-Step RIC Allogeneic HSCT for Hematologic Malignancies
NCT02566304Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2015
- Primary completion
- Feb 2024
- Modality
- Cell Therapies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludarabine, cyclophosphamide and T-cell-depleted donor lymphocyte infusion in acute myeloid leukemia (AML), aplastic anemia, chronic myelomonocytic leukemia (CMML) and 5 more, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2015; status: completed.
02
Drugs
fludarabinecyclophosphamideT-cell-depleted donor lymphocyte infusion
03
Conditions
acute myeloid leukemia (AML)aplastic anemiachronic myelomonocytic leukemia (CMML)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02566304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566304.